The global dasatinib drugs market size is projected to reach US$ 6.53 billion by 2030, from US$ 4.35 billion in 2023, at a CAGR of 6.0% during the forecast period 2023-2030. Dasatinib is a drug that is used to treat leukemia and other cancers. It belongs to a class of drugs called Tyrosine Kinase Inhibitors (TKIs). Dasatinib was the first TKI approved for the treatment of chronic myeloid leukemia (CML). It is also approved for the treatment of acute lymphoblastic leukemia (ALL), non-small cell lung cancer, and pancreatic cancer. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management.
Get a Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5963
Our Sample Report May Includes:
‣ 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
‣ 115+ Pages Research Report (Inclusion of Updated Research).
‣ Provide Chapter-wise guidance on Requests.
‣ 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
‣ Includes Updated List of tables & figures.
‣ Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Dasatinib Drugs Market Drivers
Extension of approved indications: Dasatinib’s approved indications have grown over time. Dasatinib’s initial approval was for CML, however it has now been expanded to encompass Ph+ ALL and some solid tumours, namely gastrointestinal stromal tumours (GIST). The market potential for dasatinib medications is increased by the expansion of indications.
Positive clinical results: In patients with CML and Ph+ ALL, dasatinib has shown notable efficacy and increased survival rates. It lessens the burden of tumours by preventing the action of particular proteins involved in the formation of cancer. Dasatinib’s market demand is influenced by its favourable safety profile and favourable clinical outcomes.
Dasatinib Drugs Market Opportunities
Expansion into emerging markets: Dasatinib medications have a great possibility to enter and grow in emerging markets. The prevalence of cancer is frequently rising in these areas, and the need to upgrade the healthcare system is becoming more and more important. By increasing their market share, forging strategic alliances, and meeting the unmet medical requirements of these markets, pharmaceutical companies can take advantage of these opportunities.
Creation of generic versions: As the dasatinib drug patent exclusivity period expires, this presents a chance for the creation and introduction of generic variants. Patients and healthcare systems may benefit from cost savings from generic medications, which would increase access to and affordability of treatment. To capitalise on this market opportunity, pharmaceutical companies can investigate the creation of generic dasatinib medications.
Dasatinib Drugs Market: Competitive Landscape
Key companies covered as a part of this study include: Bristol-Myers Squibb Company, Novartis International AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Ltd., Hetero Drugs Limited, Natco Pharma Limited, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd.
- Global Dasatinib Drugs Market, By Demographic:
- Global Dasatinib Drugs Market, By Behavior
- Prescription Patterns
- Treatment History
- Global Dasatinib Drugs Market, By Psychographic
- Attitudes and Beliefs
- Global Dasatinib Drugs Market, By Demographic:
Get Exclusive Purchase Now to Access @ https://www.coherentmarketinsights.com/insight/buy-now/5963
Dasatinib Drugs Market Trends
Growing use of targeted therapies: The market for dasatinib pharmaceuticals has been greatly impacted by the growing use of targeted therapies in oncology. Tyrosine kinase inhibitors (TKIs), which specifically inhibit the action of particular proteins implicated in cancer progression, include dasatinib in their class of targeted medicines. Dasatinib and other TKIs are anticipated to be more in demand as targeted medicines continue to be accepted and exhibit positive clinical outcomes.
Combination medicines receiving more attention: Dasatinib-based combinations are receiving more interest in the field of oncology. Dasatinib has the potential to have synergistic effects when combined with other targeted treatments, immunotherapies, or traditional chemotherapeutic drugs. Combination therapies are becoming more popular as a result of pharmaceutical corporations and researchers experimenting with various combinations to improve therapeutic efficacy and combat drug resistance.
Dasatinib Drugs Market: Recent Developments
New product launches
As of June 2023, there haven’t been any new dasatinib medicine introductions on the market. The chemotherapeutic drug dasatinib is sold under the trade name Sprycel. It is used to treat a few cases of acute lymphoblastic leukaemia (ALL) and chronic myelogenous leukaemia (CML). The FDA initially approved the medication in 2006, and it is currently offered in a variety of dose strengths.
Several clinical trials assessing brand-new dasatinib formulations, including a monthly injectable formulation and a nanoparticle formulation, were conducted in 2022. However, these trials haven’t led to the development of any new items.
Acquisition and partnerships
2019 saw the $74 billion acquisition of Celgene Corporation by Bristol-Myers Squibb (BMS). With this acquisition, BMS gained control of Sprycel, a dasatinib medication from Celgene and one of the most effective CML therapies.
Global Blood Therapeutics (GBT) was purchased by LUCIUS Pharma for $3.9 billion in 2020. The dasatinib-based therapeutic candidate GBT440, which is being developed as a sickle cell disease treatment, was made available to LUCIUS Pharma as a result of this acquisition.
Ask Here for Customization Report @ https://www.coherentmarketinsights.com/insight/request-customization/5963
Reasons to Purchase this Report:
👉Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
👉Provision of market value (USD Billion) data for each segment and sub-segment
👉Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
👉Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
👉The current as well as future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
👉Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
👉Market dynamics scenario, along with growth opportunities of the market in the years to come.
Check Out More Report:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
📞United States of America: +1-206-701-6702
📞United Kingdom: +44-020-8133-4027